



# Nicox to present at the 14<sup>th</sup> Annual BIO Investor Forum

October 13, 2015

Sophia Antipolis, France

**Nicox S.A.** (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 14<sup>th</sup> Annual BIO Investor Forum in San Francisco on Tuesday October 20, 2015, at 10:00 am Pacific Time.

A live webcast of the BIO Investor Forum presentation can be accessed under the “Presentations & webcasts” page within the News & Media section of the company’s website at [www.nicox.com](http://www.nicox.com). A replay of the webcast will be archived on the Nicox website for 90 days following the date of the presentation.

## About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.

Nicox’s advanced pipeline features VESNEO™ for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was recently submitted to the FDA by the Company’s licensee Valeant. Our pipeline also features: AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis; AzaSite®, a pre-MAA candidate in Europe for bacterial conjunctivitis; and BromSite™, a pre-MAA candidate in Europe for pain and inflammation after cataract surgery. The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors.

Nicox is headquartered in France and has more than 130 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its commercial products or pipeline, please visit [www.nicox.com](http://www.nicox.com).

## Upcoming 2015 events

### Financial and business conferences

Nov.5	Société Générale Healthcare Forum	Paris, France
Nov. 12-13	Bryan Garnier Healthcare Conference	Paris, France
Nov.20-21	Actionaria 2015	Paris, France
Nov.24	Natixis MidCap Conference	Paris, France

### Scientific conferences

Nov. 14-17	AAO – American Academy of Ophthalmology	Las Vegas, US
Nov. 27-30	SOI National Congress	Rome, Italy

## Analyst coverage

Bryan, Garnier & Co  
Stifel  
Invest Securities  
Kepler Cheuvreux

Hugo Solvet  
Max Herrmann  
Martial Descoutures  
Alexandra Ralli

Paris, France  
London, UK  
Paris, France  
Paris, France



---

## Contacts

### Nicox

**Gavin Spencer** | Executive Vice President Corporate Development  
**Caroline Courme** | Communication Manager  
Tel +33 (0)4 97 24 53 43 | [communications@nicox.com](mailto:communications@nicox.com)

### Media Relations

#### United Kingdom

**Jonathan Birt**  
Tel +44 7860 361 746 | [jonathan.birt@gmail.com](mailto:jonathan.birt@gmail.com)

#### France

**NewCap** | Nicolas Merigeau  
Tel +33 (0)1 44 71 94 98 | [nicox@newcap.fr](mailto:nicox@newcap.fr)

#### United States

**Argot Partners** | Eliza Schleifstein  
Tel +1 (917) 763-8106 | [eliza@argotpartners.com](mailto:eliza@argotpartners.com)

### Investor Relations

#### Europe

**NewCap** | Julien Perez | Valentine Brouchet  
Tel +33 (0)1 44 71 94 94 | [nicox@newcap.fr](mailto:nicox@newcap.fr)

#### United States

**Argot Partners** | Melissa Forst  
Tel +1 (212) 600-1902 | [melissa@argotpartners.com](mailto:melissa@argotpartners.com)

---

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4<sup>th</sup> chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2014' filed with the French *Autorité des Marchés Financiers* (AMF) on April 10, 2015, which is available on Nicox's website ([www.nicox.com](http://www.nicox.com)).